PLX - Protalix signals $100M+ Elfabrio royalties by 2030 as Phase II PRX-115 trial advances
2025-08-14 12:48:40 ET
More on Protalix BioTherapeutics
- Protalix BioTherapeutics, Inc. (PLX) Q2 2025 Earnings Call Transcript
- Protalix BioTherapeutics appoints Gilad Mamlok as CFO
- Seeking Alpha’s Quant Rating on Protalix BioTherapeutics
- Historical earnings data for Protalix BioTherapeutics
- Financial information for Protalix BioTherapeutics